Development of [18F]DASA-10 for enhanced imaging of pyruvate kinase M2

Purpose: The aim of this study was to develop a positron emission tomography (PET) radiotracer for measuring pyruvate kinase M2 (PKM2) with improved physicochemical and pharmacokinetic properties compared to [18F] DASA-23.Experimental design: First, we synthesized [18F]DASA-10 and tested its uptake and retention compared to [18F] DASA-23 in human and mouse glioma cell lines. We then confirmed the specificity of [18F]DASA-10 by transiently modulating the expression of PKM2 in DU145 and HeLa cells. Next, we determined [18F]DASA-10 pharmacokinetics in healthy nude mice using PET imaging and subsequently assessed the ability of [18F]DASA10 versus [18F]DASA-23 to enable in vivo detection of intracranial gliomas in syngeneic C6 rat models of glioma. Results: [18F]DASA-10 demonstrated excellent cellular uptake and retention with values significantly higher than [18F]DASA-23 in all cell lines and timepoints investigated. [18F]DASA-10 showed a 73 % and 65 % reduced uptake respectively in DU145 and HeLa cells treated with PKM2 siRNA as compared to control siRNA treated cells. [18F]DASA-10 showed favorable biodistribution and pharmacokinetic properties and a significantly improved tumor-to-brain ratio in rat C6 glioma models relative to [18F]DASA-23 (3.2 & PLUSMN; 0.8 versus 1.6 & PLUSMN; 0.3, p = 0.01).Conclusion: [18F]DASA-10 is a new PET radiotracer for molecular imaging of PKM2 with potential to overcome the prior limitations observed with [18F]DASA-23. [18F]DASA-10 shows promise for clinical translation to enable imaging of brain malignancies owing to its low background signal in the healthy brain.

Automated summary

This study aimed to develop a new PET radiotracer [18F] DASA-10 for measuring pyruvate kinase M2 (PKM2). Compared to [18F] DASA-23, [18F] DASA-10 demonstrated improved pharmacokinetic properties and cellular uptake and retention in glioma cell lines. In rat glioma models, [18F] DASA-10 showed a better tumor-to-brain ratio.